Ferrosan Medical Devices A/S
Ferrosan Medical Devices is known for developing and producing medico products in bleeding medicine technology and biopsy devices for cancer diagnostics.
Since 1947, FeMD has developed and manufactured surgical haemostatic devices for use by healthcare professionals. In this context, FeMD has a global partnership agreement with US-based Ethicon, Inc. (part of Johnson & Johnson), which is responsible for sales and marketing of FeMD’s haemostatic devices in more than 100 countries. In addition, FeMD develops and produces handheld biopsy devices, used in the diagnosis of breast cancer. These are developed and distributed in collaboration with a global partner.
The Danish medical device company has around 350 employees and production facilities in Søborg in Denmark and Szczecin in Poland. In 2021, FeMD had revenues totalling DKK 720 million and an EBITDA of DKK 281 million, and has recorded annual revenue growth of 14% over the past 10 years. In 2010, FeMD was established as an independent legal entity. Prior to that, FeMD had been part of the Ferrosan A/S group, which until 1995 was owned by Novo Nordisk A/S.
The Lundbeck Foundation owns around 30% of FeMD.